Drug maker Lupin is expected to report a 36 percent growth year-on-year in profit at Rs 550 crore for the quarter ended September 2014 due to better operating performance and low base in same quarter last year, according to the average of estimates of analysts polled by CNBC-TV18. Profit in Q2FY14 was Rs 406.2 crore. Earnings will be announced on Tuesday.
Revenue may rise 23 percent to Rs 3,270 crore in the second quarter of current financial year 2014-15 compared to Rs 2,668 crore in the year-ago period driven by strong growth in US.
Analysts expect strong growth in US territory but that may not be as high as Q1, where it grew by 57 percent Y-o-Y and 24 percent Q-o-Q to USD 262 million. They expect USD 10 million sequential growth in US business.
According to them, US sales may taper off due to additional competition in Cymbalta (used to treat major depressive disorder) and Niaspan (used in reducing cholesterol) but growth in US may be driven by drugs such as Trizivir, Trilipix, Actos and Cipro.
Analysts expect India to grow 15-16 percent as against 29 percent Y-o-Y growth in Q1FY15 while rest of the world markets could pick up in the quarter with 10 percent growth (as against only 4 percent growth in Q1).
Operating profit is seen going up by 36 percent on yearly basis to Rs 896 crore and margin may expand 270 basis points to 27.4 percent in the quarter gone by.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
